11 Myths About Blood Tests and Hormone Levels That Keep Women Undiagnosed During Perimenopause
Getting a 'your levels are fine' result while feeling absolutely not fine is one of the most gaslighting experiences of perimenopause. The number of women who've been sent away, told to try antidepressants, or simply reassured it's 'just stress' — because their FSH came back in range — is genuinely heartbreaking. Blood tests have their place, but they were never meant to be the whole story.
Learn more about Rose →Myth: A normal FSH result rules out perimenopause
FSH (follicle-stimulating hormone) rises on average as ovarian reserve declines, but during early and mid-perimenopause it fluctuates dramatically — sometimes reading completely normal on the day of the test while being elevated a week later. A single FSH measurement is essentially a snapshot of one moment in an extremely variable process. The 2023 NAMS guidelines explicitly state that FSH levels alone are insufficient to diagnose or exclude perimenopause in women over 40.
Myth: Estradiol levels accurately reflect how much estrogen your body is producing day to day
Estradiol during perimenopause doesn't decline in a smooth, predictable line — it surges, crashes, and surges again, sometimes within the same week. Research published in the journal Menopause has documented estradiol levels fluctuating by as much as 300% across a single menstrual cycle during the transition. Testing on any given day captures only a single data point in a process that resembles a volatile stock chart far more than a steady decline.
Myth: You need to be in the 'menopausal range' to be experiencing perimenopausal symptoms
Some of the most severe perimenopausal symptoms — including migraines, rage, anxiety, and heavy bleeding — occur during phases of estrogen excess or rapid estrogen fluctuation, not estrogen deficiency. This means a woman can have estradiol levels that look high or normal on a test while simultaneously experiencing debilitating symptoms driven by hormonal volatility. Waiting for levels to drop into a 'menopausal range' before offering support is not evidence-based practice.
Myth: Symptom-based diagnosis is less reliable than a blood test
The clinical reality is the opposite: validated symptom questionnaires such as the Greene Climacteric Scale and the Menopause Rating Scale have demonstrated strong diagnostic utility in research settings. A woman's lived symptom pattern — particularly the constellation of irregular cycles, sleep disruption, vasomotor symptoms, and mood changes — is a more consistent diagnostic signal than a single hormone panel. Leading menopause societies, including the British Menopause Society, explicitly endorse symptom-based diagnosis for women over 45.
Myth: GPs and gynecologists can time a blood test to 'catch' perimenopausal hormonal changes
The unpredictability of perimenopausal hormonal fluctuation means there is no reliable window in the cycle to draw blood and expect a representative result. The Study of Women's Health Across the Nation (SWAN) — one of the largest longitudinal studies of the menopause transition — demonstrated that within-woman variability in FSH and estradiol is so high during perimenopause that repeated measurements add little diagnostic clarity. Timing a test precisely does not resolve the fundamental problem of intra-cycle volatility.
Myth: Blood tests are the standard diagnostic tool recommended by menopause guidelines
NICE Guideline NG23 — the UK's national clinical guideline on menopause — explicitly states that blood tests should not be used to diagnose perimenopause in women aged 45 and over, and that diagnosis should be based on symptoms alone. Despite this clear guidance having been in place since 2015 and updated since, a significant proportion of women still report being told their symptoms cannot be attributed to perimenopause without a confirming blood result. The guideline exists precisely because the evidence showed tests were creating diagnostic barriers rather than clarity.
Myth: Low testosterone in women is reliably detected by standard blood panels
Standard NHS and most US laboratory testosterone assays are calibrated for male reference ranges and are not sensitive enough to detect the subtle but clinically meaningful differences in female testosterone levels. Women's testosterone typically sits at roughly one-tenth of male levels, meaning many standard tests simply lack the resolution to pick up changes that are physiologically significant for women. Low libido, fatigue, and reduced motivation attributed to 'normal ageing' may reflect testosterone changes that a standard blood panel simply cannot detect.
Myth: If your thyroid panel is normal, thyroid issues aren't contributing to your symptoms
Perimenopause and thyroid dysfunction share a substantial symptom overlap — fatigue, brain fog, weight changes, mood disturbance, and irregular cycles appear in both conditions. A standard TSH test may sit within the laboratory reference range while still sitting at a level that contributes to symptoms for some individuals, particularly those whose TSH has shifted significantly from their personal baseline. Given that women in their 40s are also at peak risk for developing autoimmune thyroid conditions, a normal TSH should be interpreted alongside symptoms rather than used to close the diagnostic conversation.
Myth: Progesterone blood tests give an accurate picture of progesterone's role in perimenopausal symptoms
Progesterone is largely produced after ovulation, so testing at the wrong point in the cycle renders the result meaningless — and during perimenopause, cycles become increasingly anovulatory, meaning progesterone may genuinely be low regardless of cycle day. Beyond production levels, the ratio of progesterone to estrogen matters as much as the absolute number, and standard panels rarely interpret the two in relation to each other. Sleep disruption and anxiety, two hallmark perimenopausal symptoms, are closely tied to progesterone's action on GABA receptors — a relationship that a raw serum number does not capture.
Myth: Women under 45 with perimenopausal symptoms just need to wait and retest later
Premature ovarian insufficiency (POI) affects approximately 1 in 100 women under 40 and a higher proportion between 40 and 45, yet these women are routinely told their symptoms are too early to be hormonal without a blood test to confirm. Even setting POI aside, the menopausal transition can begin in the early-to-mid 40s and sometimes earlier, and delaying support while waiting for labs to 'catch up' means years of unmanaged symptoms that carry their own health consequences, including bone loss and cardiovascular risk. Age under 45 is not a reason to dismiss a symptom pattern — it is a reason to investigate more thoroughly.
Myth: Once hormone levels stabilise post-menopause, blood tests become reliable enough to guide treatment
While hormone levels are less volatile after the final menstrual period, significant individual variation in baseline estradiol, SHBG (sex hormone-binding globulin), and testosterone means that population-level reference ranges remain a poor substitute for symptom-guided clinical assessment. SHBG in particular is rarely tested on standard panels despite binding a significant proportion of circulating sex hormones and dramatically affecting their bioavailability — meaning a woman's 'free' hormone levels can differ substantially from her total measured levels. Post-menopausal blood testing informs but should never override what a woman is actually experiencing.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.